Herbert Lyerly
George Barth Gellar Professor of Cancer Research
Professor of Surgery
Professor of Pathology
Professor in Immunology
Contact
lyerl001@mc.duke.edu(919) 681-8350
203 Research Drive, Suite 433
View Website Download C.V.Appointment:
Herbert Lyerly
George Barth Gellar Professor of Cancer Research
Professor of Surgery
Professor of Pathology
Professor in Immunology
Clinical Interests:
Surgical treatment of breast cancer; gene- and immune-based therapy for breast, kidney, lung, colon, and pancreatic cancers
Publications
-
Dailey GP, Rabiola CA, Lei G, Wei J, Yang X-Y, Wang T, et al. Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer. Hum Vaccin Immunother. 2024 Dec 31;20(1):2309693.Pandey S, Cholak ME, Yadali R, Sosman JA, Tetreault M-P, Fang D, et al. Immune Assessment Today: Optimizing and Standardizing Efforts to Monitor Immune Responses in Cancer and Beyond. Cancers (Basel). 2024 Jan 23;16(3).Bhagat A, Lyerly HK, Morse MA, Hartman ZC. CEA vaccines. Hum Vaccin Immunother. 2023 Dec 15;19(3):2291857.Trotter TN, Dagotto CE, Serra D, Wang T, Yang X, Acharya CR, et al. Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3. JCI Insight. 2023 Nov 22;8(22).
See more publications at Scholars@Duke